Table 2. FLT3 mutation data and... | American Society of Hematology

Table 2.

FLT3 mutation data and presentation clinical parameters for patient samples studied in Western blotting experiments

							MTS IC₅₀, nM
No.	Sex	Age, y	FAB type	Presenting WBC count, × 10⁹/L	Mutation type^*	% mutant RNA†	Lestaurtinib	PKC412
M-1	F	74	M1	140.7	ITD 33 bp	34	44	647
M-2	F	40	M1	112.8	ITD 40 bp	84	173	++
M-3	F	56	M4	73.6	ITD 25 bp	7	++	++
M-4	F	66	M2	52.5	ITD 33 bp	18	178	++
M-5	F	39	M4	230.2	ITD 60 bp	30	95	320
M-6	M	45	M4	162.0	ITD 24 bp	62	14	704
M-7	M	71	M1	50.5	D835Y	45	24	32
W-1	M	18	M1	29.0	WT	—	++	++
W-2	M	17	M1	75.0	WT	—	++	++
W-3	NA	42	M5	150.0	WT	—	42	312
W-4	F	44	n/a	190.0	WT	—	++	++
W-5	F	41	n/a	n/a	WT	—	69	++

							MTS IC₅₀, nM
No.	Sex	Age, y	FAB type	Presenting WBC count, × 10⁹/L	Mutation type^*	% mutant RNA†	Lestaurtinib	PKC412
M-1	F	74	M1	140.7	ITD 33 bp	34	44	647
M-2	F	40	M1	112.8	ITD 40 bp	84	173	++
M-3	F	56	M4	73.6	ITD 25 bp	7	++	++
M-4	F	66	M2	52.5	ITD 33 bp	18	178	++
M-5	F	39	M4	230.2	ITD 60 bp	30	95	320
M-6	M	45	M4	162.0	ITD 24 bp	62	14	704
M-7	M	71	M1	50.5	D835Y	45	24	32
W-1	M	18	M1	29.0	WT	—	++	++
W-2	M	17	M1	75.0	WT	—	++	++
W-3	NA	42	M5	150.0	WT	—	42	312
W-4	F	44	n/a	190.0	WT	—	++	++
W-5	F	41	n/a	n/a	WT	—	69	++

++ indicates IC₅₀ not reached at 200 nM lestaurtinib or 1000 nM PKC412; n/a, not available; and —, not applicable

FLT3 ITD with size in number of base pairs or TKD point mutation

Mutant FLT3 RNA expression as a percent of total FLT3 RNA expression